Global Human Microbiome Industry Outlook to 2030: Type of Therapy, Type of Molecule, Target Indication, Therapeutic Area, Supply Channel, Leading Drug Developers, Leading Therapeutic ProductsHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Global Human Microbiome Industry Outlook to 2030: Type of Therapy, Type of Molecule, Target Indication, Therapeutic Area, Supply Channel, Leading Drug Developers, Leading Therapeutic ProductsGlobeNewswireJanuary 3, 2020ReblogShareTweetShareDublin, Jan. 03, 2020 (GLOBE NEWSWIRE) -- The "The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030" report has been added to ResearchAndMarkets.com's offering.This report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across:[A] type of therapy (prescription drugs, prebiotics, and probiotics)[B] type of molecule (small molecules and biologics)[C] target indication (acne vulgaris, atopic dermatitis, CDI, Crohn's disease, diabetes, irritable bowel syndrome, lactose intolerance, nonalcoholic steatohepatitis (NASH), ulcerative colitis, and 5+ categories)[D] therapeutic area (autoimmune disorders, dental disorders, digestive and gastrointestinal disorders, dermatological disorders, infectious diseases, metabolic disorders, oncology, and others)[E] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies)[F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world)[G] leading drug developers[H] leading therapeutic productsIn addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across:[A] target indication (Crohn's disease, colorectal cancer, diabetes, irritable bowel syndrome, lung cancer, NASH, obesity, and ulcerative colitis)[B] therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncology)[C] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies)[D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world)In addition to other elements, the study includes:A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe. A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
Key Topics Covered 1. PREFACE1.1. Scope of the Report1.2. Research Methodology1.3. Chapter Outlines2. EXECUTIVE SUMMARY3. INTRODUCTION3.1. Chapter Overview3.2. Concept of Microbiota and Microbiome3.3. Overview of Gut Flora3.4. The Microbiome and Disease3.5. Impact of Microbiota on Drug Pharmacokinetics3.6. Impact of Microbiota on Therapeutic Outcomes3.7. Microbiome Therapeutics3.8. The Human Microbiome Project (HMP)3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)3.10. Key Challenges in the Development of Microbiome Therapeutics3.11. Future Perspectives4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE4.1. Chapter Overview4.2. Microbiome Therapeutics: Clinical Pipeline4.3. Microbiome Therapeutics: Early-Stage Pipeline4.4. Microbiome Therapeutics: List of Drug Developers4.5. Microbiome Therapeutics: List of Discontinued Drugs4.6. Emerging Role of Microbiome in Gut-Brain Axis4.7. Microbiome Therapeutics: List of Technology Platforms5. COMPANY AND DRUG PROFILES5.1. Chapter Overview5.2. 4D Pharma5.3. Armata Pharmaceuticals5.4. Evelo Biosciences5.5. Rebiotix (Acquired by Ferring Pharmaceuticals)5.6. Seres Therapeutics5.7. Vedanta Biosciences6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE6.1. Chapter Overview6.2. Overview of Microbiome Diagnostic Tests6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers6.5. Profiles of Prominent Diagnostic Developers6.6. Overview of Microbiome Screening / Profiling Tests7. FECAL MICROBIOTA THERAPY (FMT)7.1. Chapter Overview7.2. Introduction to FMT7.3. Historical Overview7.4. FMT: Procedure and Clinical Relevance7.5. Regulatory Guidelines Related to FMT7.6. Insurance Coverage for FMT7.7. FMT: Competitive Landscape7.8. Clinical Trial Analysis (Non-Industry Sponsored)7.9. Stool Banks8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX8.1. Chapter Overview8.2. AC Matrix: An Overview8.3. AC Matrix: Analytical Methodology8.4. AC Matrix: Plotting the Information8.5. AC Matrix: Analyzing the Data8.6. Concluding Remarks9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS9.1. Chapter Overview9.2. Scope and Methodology9.3. Initiatives of Big Pharmaceutical Players9.4. Benchmark Analysis of Big Pharmaceutical Players10. START-UP HEALTH INDEXING10.1. Chapter Overview10.2. Scope and Methodology10.3. Benchmark Analysis of Start-ups11. KEY THERAPEUTIC AREAS11.1. Chapter Overview11.2. Metabolic Disorders11.3. Digestive and Gastrointestinal Disorders11.4. Oncological Indications11.5. Dermatological Disorders11.6. Infectious Diseases12. FUNDING AND INVESTMENT ANALYSIS12.1. Chapter Overview12.2. Types of Funding12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments12.4. Concluding Remarks13. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS13.1. Chapter Overview13.2. Manufacturing Microbiome Therapeutics13.3. Microbiome Therapeutics-related R&D13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner14. BIG DATA AND MICROBIOME THERAPEUTICS14.1. Chapter Overview14.2. Introduction to Big Data14.3. Internet of Things14.4. Growing Interest in Big Data: Google Trends Analysis14.5. Key Application Areas14.6. Big Data in Microbiome Research14.7. Big Data Services for Microbiome Research: List of Companies14.8. Big Data Services for Microbiome Research: Profiles of Key Players15. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS15.1. Chapter Overview15.2. Scope and Limitations15.3. Forecast Methodology15.4. Overall Microbiome Therapeutics Market, 2019-203015.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-203016. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS16.1. Chapter Overview16.2. Scope and Limitations16.3 Forecast Methodology16.4. Overall Microbiome Diagnostics Market, 2019-203016.5. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-203016.6. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-203016.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-203016.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-203017. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS17.1. Chapter Overview17.2. Scope and Limitations17.3. Forecast Methodology17.4. Overall FMT Market, 2019-203017.5. Overall Microbiome Market by Product Offerings, 2019-203018. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES18.1. Chapter Overview18.2. List of Microbiome Products in Other Industries18.3. Applications of Microbiome Based Products in Agriculture Industry18.4. Future Prospects19. CONCLUDING REMARKS20. EXECUTIVE INSIGHTS20.1 Chapter Overview20.2. Rebiotix20.3. S-Biomedic20.4. Whole Biome20.5. Siolta Therapeutics20.6. OpenBiome20.7 Assembly Biosciences20.8. List Biological Laboratories20.9. Metabiomics20.10. MicroBiome Therapeutics20.11. Universal Stabilization Technologies20.12. BiomX20.13. Da Volterra20.14. Chung Mei Pharmaceutical20.15. Pacific Northwest National Laboratories21. APPENDIX I: TABULATED DATA22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONSStory continues16S Technologies4D Pharma5QBD-BiotechAalborg University HospitalAarhus UniversityAB-BioticsAbbott LaboratoriesAbbVieAbraxis BioScienceAcademic Medical Centre (Amsterdam UMC)ActoBio TherapeuticsAdapsyn BioscienceAdare PharmaceuticalsAdvancingBioAEProbioAetnaAgBiomeAjuvis LabsdAlaven PharmaceuticalAleris-Hamlet HospitalAlimentary Health (Part of PrecisionBiotics Group)Alimentary Pharmabiotic Centre Microbiome Institute, University College Cork (UCC)AllerganAllergy TherapeuticsAltis BiosystemsAmabioticsAmazonAmerican College of GastroenterologyAmpleAmpliPhi BiosciencesAmrita TherapeuticsAnavex Life SciencesAnimalBiomeANIZOMEAOBiome TherapeuticsArdigenArena PharmaceuticalsArizona State UniversityArmata PharmaceuticalsArtizan BiosciencesARTPredAscus BiosciencesAsia Microbiota BankAsiaBiome (formely known as Civet Biosciences)Assaf Harofeh Medical CenterAssembly BiosciencesAPHM (Public Assistance - Marseille Hospitals)APHP (Public Assistance - Paris Hospitals)Astarte MedicalAstel MedicaAstraZenecaAtlas BiomedAutonomous University of Nuevo LenAventis PharmaAvidBioticsAxcan PharmaAxial BiotherapeuticsAzitraBactanaBayerBaylor College of MedicineBecton DickinsonBeiersdorfBeth Israel Deaconess Medical CenterBio FarmaBiocartisBiocodexBioControl (Acquired by Merck)BioGaiaBiogenBiohit HealthcareBIOHM HealthBio-K Plus InternationalBiom PharmaceuticalsBioMathematicaBiomCareBio-MeBiome MakersBiome360BiomeBlissBiomecite DiagnosticsBiomeSenseBiomica (subsidiary of Evogene)BiomilleniaBiomXBioRankingsBiorasibioseBiotagenicsBlis ProbioticsBlue BiologyBlue Turtle BioBoehringer IngelheimBoobyBiomeBoston Children's HospitalBoston Medical CenterBrigham and Women's HospitalBristol-Myers SquibbBugSpeakCaelus HealthCalifornia Institute of Technology (Caltech)Campus Bio-Medico UniversityCanadian Association of GastroenterologyCanadian Institutes of Health ResearchCapsugelCaptozymeCarbiotixCARB-XCareggi University HospitalCase Comprehensive Cancer CenterCatholic University of the Sacred HeartCedars-Sinai Medical CenterCenter for Microbiome Informatics and Therapeutics, Massachusetts Institute of TechnologyCenter of Food and Fermentation TechnologiesCenters for Disease Control and PreventionCHAIN BiotechnologyCharles River LaboratoriesChildren's Hospital Los AngelesChildren's Hospital of PhiladelphiaChildren's Mercy Hospital Kansas CityChr. HansenChugai PharmaceuticalChung Mei PharmaceuticalChunLabCignaCIPAC HealthcareClasado BioSciencesClearB TherapeuticsClinical Investigation Center for Innovative Technology NetworkClinical MicrobiomicsClostraBioCobra BiologicsCommense (a subsidiary of PureTech Health)Concentric AgCook MyoSiteCoreBiomeCornell UniversityCosmosIDCovarisCRB-HUEPCrohn's & Colitis FoundationCRS BioCykinsoDairy & Food Culture TechnologiesDakota BioTechDaniscoDa VolterraDayanand Medical College & HospitalDayTwoDermBiontDiagnostic Solutions LaboratoryDiversigenDNA GenotekDuke UniversityDuPontEagle GenomicsEat TrooEatricsEdico Genome (Acquired by Illumina)EirGenixEli LillyELiE Health SolutionsEmbion TechnologiesEmblemHealthEmory UniversityEmulateEnglewood HealthEnterinEnteroBiotixEnterome BioscienceEpiBiome (Acquired by Locus Biosciences)Esse SkincareEuropean CommissionEuropean Society of Clinical Microbiology and Infectious DiseasesEvelo BiosciencesEvolve BioSystemsEvotecEXDENExeliom Biosciences (formerly known as Nextbiotix)EzBioCloudFecal Microbiota Transplantation WorkgroupFederal Research and Clinical Center of Physical-Chemical MedicineFermBioticsFerring PharmaceuticalsFinch TherapeuticsFirst Affiliated Hospital of Chengdu Medical CollegeFlora MedicineFloragraphFirst Affiliated Hospital of Nanchang UniversityFortifyFoundation of HopeFourth Military Medical UniversityFrontier Science & Technology Research FoundationFUJIFILM Diosynth BiotechnologiesFuzhou General HospitalG.D SearleGaldermaGallineGALTGenetic AnalysisInstitute of Molecular Genetics Academy of Sciences Czech RepublicGENEWIZGenome and CompanyGenova DiagnosticsGenten TherapeuticsGerman Federal Ministry of Education and ResearchGhent UniversityGI InnovationGinkgo BioworksGlobal CosmeticsGNUbiotics SciencesGoodBellyGoodGutGroken BioscienceGlaxoSmithKlineGT BiologicsGuangzhou First People's HospitalGlhane Institute of Health SciencesGusto GlobalHadassah Medical CenterHamilton Health SciencesHarvest Capital StrategiesHaukeland University HospitalHealth NetHealthPartnersUniversity of HelsinkiHoechst Marion RousselHolobiomeHospital District of Helsinki and UusimaaHospital for Sick ChildrenHospital Ramn y CajalHudson Institute of Medical ResearchHuman LongevityHunter Holmes McGuire Veterans Administration Medical CenterHvidovre HospitalHy LaboratoriesHyggutIBMIcahn School of Medicine at Mount SinaiiCarbonXIgen Biolab GroupImClone SystemsImmuneBiotechImmunexImmuronIndiana UniversityIndigo TherapeuticsInsermInstitut AllergosanInstitut national de la recherche agronomiqueInstitute for Clinical and Experimental MedicineThe Institute of Animal PhysiologyInstitute of Liver and Biliary SciencesIntralytixIntrexonIntuition BiosciencesInvivo HealthcareIpsat TherapiesIronwood PharmaceuticalsIS-DiagnosticsIsland HealthIsohelixISOThriveIxcelaIxion BiotechnologyJ. Craig Venter InstituteJanssen BiotechJena University HospitalJinling HospitalJohn Theurer Cancer CenterJohnson & JohnsonJoint Authority for Pijt-Hme Social and Health CareJuno BioKaleido BiosciencesKallyopeKarolinska InstitutetKelsey Research FoundationKeystone BioKing's College LondonKingston Health Sciences CentreKintai TherapeuticsKNOMICS MICROBIOTAKobiolabsLa Trobe UniversityLaboratorio CobasLactobioLallemand Health SolutionsLavie BioLawrence Berkeley National LaboratoryLawson Health Research InstituteLeadiant BiosciencesLeiden UniversityLesaffre Human CareLevanger HospitalList Biological LaboratoriesLNC TherapeuticsLocus BiosciencesLondon Health Sciences CentreLonzaLovisenberg Diakonale HospitalLUCA BiologicsLuina BioLuxia ScientificM.D. Anderson Cancer CenterMaaT PharmaMadison UniversityMaiden TherapeuticsMankind PharmaManufacturer Vilhelm Pedersen FoundationMarqus de Valdecilla University HospitalMasonic Cancer CenterMassachusetts General HospitalMassachusetts Institute of TechnologyMatriSys BioscienceMayo ClinicMcMaster UniversityMD Anderson Cancer CenterMedeva PharmaceuticalsMedical College of WisconsinMedical University of GrazMedlabMemorial Medical Center FoundationMemorial Sloan Kettering Cancer CenterMemorial University of NewfoundlandMemorialCare Health SystemMerckMerge HealthcareMetabiomicsMetaboGenMichael E. DeBakey Veterans Affairs Medical CenterMitchell Cancer InstituteMicrobaMicrobiome Diagnostic PartnersMicrobiome Health Research InstituteMicrobiome InsightsMicrobiome Research CentreMicroBiome TherapeuticsMicrobiome Therapeutics Innovation GroupMicrobiomeDxMicrobioticaMicroinventaMicrosoftMicroviable TherapeuticsMillennium PharmaceuticalsMiomicsMiyarisan PharmaceuticalModena University HospitalMolzymMonash UniversityMontefiore Medical CenterMoon BiotechMount Sinai HospitalmybacsMyBioticsMyMicroZooNAFLD Research Center, University of California San Diego School of MedicineNaked BiomeNantes University HospitalNational Cancer Institute (NCI)The National Institute for Health and Care Excellence (NICE)National Institute of Allergy and Infectious Diseases (NIAID)The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)National Institute for Health and Medical Research (INSERM)National Institutes of Health (NIH)National Jewish HealthNational PKU AllianceNationwide Children's HospitalNestl Health ScienceNew York UniversityNew Zealand Society of GastroenterologyNIZONordland Hospital TrustNorthShore University HealthSystemNorway Regional Health AuthorityNorwegian University of Science and TechnologyNovartisNovo NordiskNovogeneNovome BiotechnologiesNubiyotaOpen Patient data Explorative NetworkOdense University HospitalOhio State University Wexner Medical CenterOmega BiomicsOne CodexOpenBiomeOptiBiotixOragenicsOraltaOrebro UniversityOregon State UniversityOrexigen TherapeuticsOselOSI PharmaceuticalsOslo University HospitalOxTheraPacific Northwest National Laboratory (PNNL)Paragon Bioservices (unit of Catalent Biologics)Parker Institute for Cancer ImmunotherapyVlaamse Parkinson LigaParkinson's Institute and Clinical CenterPeking Union Medical College HospitalPendulum Therapeutics (formerly known as Whole Biome)PerrigoPersona BiomePfizerPharmacia & UpjohnPharm-OlamPhase GenomicsPhi TherapeuticsPhylagenPierre and Marie Curie UniversityPierre FabrePillar HealthcarePostbiotics PlusPostgraduate Institute of Medical Education and ResearchPrecisionBioticsPresutti LaboratoriesPrime DiscoveriesPriority HealthProbioticalProdermIQProDigestPrometheus LaboratoriesPSI FoundationPsoriasis AssociationPsychiatric Hospital of the University of BaselPublic Health EnglandPublic Health OntarioPuerta de Hierro University HospitalQiaraQingdao Institute of Bioenergy and Bioprocess TechnologyQuadram InstituteQuay PharmaQueen Elizabeth II Health Sciences CentreQueen's UniversityQuorum InnovationsQuotient SciencesRambam Healthcare CampusRebiotix (part of Ferring Pharmaceuticals Group)Regence BlueShieldRegeneron PharmaceuticalsReplete BioticsResearch Foundation - FlandersResearch Institute of St Joe's HamiltonResilient BioticsResphera BiosciencesRise TherapeuticsRitter PharmaceuticalsRocheRondinX (Acquired by BiomX)Roswell Park Comprehensive Cancer CenterRuprecht Karl University of HeidelbergRush UniversitySabinsaSaint-Antoine HospitalSalix PharmaceuticalsSanofiS-BiomedicScaled MicrobiomicsSciBacScioto BiosciencesSeattle Children's HospitalSecond GenomeSeed HealthSanta Maria della Misericordia HospitalSeres TherapeuticsSFA TherapeuticsShanghai Children's Medical CenterShanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai Zhongshan HospitalSheba Medical CenterShoreline BiomeSicorSiffra FarmaceuticiSinai Health SystemSiolta TherapeuticsSjogren's Syndrome FoundationSkinBioTherapeuticsSnipr BiomeSolarea BioSoroka Medical CenterSRZ PropertiesSt. Justine's HospitalStanford Cancer InstituteStanford University School of MedicineStony Brook UniversitySucampo PharmaceuticalsSugarlogixSun GenomicsSymberixSymbiotaSymbiotix BiotherapiesSyneos HealthSynergy WorldwideSynlogicSynthetic BiologicsSynthetic GenomicsTaiho PharmaceuticalTakeda PharmaceuticalTargEDysTel Aviv Sourasky Medical CenterTemple UniversityTeva PharmaceuticalTexas Digestive Diseases CenterTexas Children's HospitalThe BioCollectiveThe Chinese University of Hong KongThe Danish Rheumatism AssociationThe Flanders Institute for BiotechnologyThe Jackson LaboratoryThe Miriam HospitalThe Research Council of NorwayThe Second Affiliated Hospital of Nanjing Medical UniversityThe University of Texas Health Science CenterThe University of Texas MD Anderson Cancer CenterThe Weston A Price FoundationThryve DigitalTongji HospitalToronto Invasive Bacterial Diseases NetworkTortuga BiosciencesTrayer BiotherapeuticsTriphase PharmaceuticalsTULA SkincareuBioDiscoveryuBiomeUCB PharmaUme UniversityUniversitair Ziekenhuis LeuvenUniversity Health NetworkUniversity Hospital CologneUniversity Hospital of LimogesUniversity Hospital of North NorwayUniversity of AdelaideUniversity of AlbertaUniversity of British ColumbiaUniversity of CalgaryUniversity of CaliforniaUniversity of ChicagoUniversity of ChietiUniversity of FlorenceUniversity of MarylandUniversity of MassachusettsUniversity of MelbourneUniversity of MiamiUniversity of MinnesotaUniversity of Modena and Reggio EmiliaUniversity of New South WalesUniversity of North CarolinaUniversity of North TexasUniversity of OsloUniversity of PennsylvaniaUniversity of PittsburghUniversity of PortsmouthUniversity of Southern DenmarkUniversity of SurreyUniversity of TexasUniversity of TorontoUniversity of TromsoUniversity of VermontUniversity of WisconsinUniversity of ZurichUS Army Medical Research and Materiel CommandUS Department of Veterans AffairsVA Office of Research and DevelopmentVaiomerVancouver General HospitalVarinosVast BiomeVedanta BiosciencesVertex PharmaceuticalsViomeVirginia Commonwealth UniversityVisbiomeViThera PharmaceuticalsVitrilifeVivusWACKER (formerly known as Synco Bio)Washington University School of MedicineWeill Cornell Medical College of Cornell UniversityWellmicroWestern Sydney Local Health DistrictWestmead Institute for Medical ResearchWinclove ProbioticsWolfson Medical CenterWomen's College HospitalXbiomeXycrobe TherapeuticsYakult HonshaYonsei UniversityZehna TherapeuticsZMD GroupFor more information about this report visit https://www.researchandmarkets.com/r/bbz676Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextCara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue EstimatesZacksCytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue EstimatesZacksFive Prime Therapeutics (FPRX) Reports Q4 Loss, Misses Revenue EstimatesZacksRevance Therapeutics, Inc. Just Reported And Analysts Have Been Cutting Their EstimatesSimply Wall St.Cidara Therapeutics (CDTX) Upgraded to Buy: What Does It Mean for the Stock?ZacksRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo Finance